- Shares of Celgene (CELG +3.3%) are moving notably higher in morning trading.
- Likely behind the move is UBS, where analyst Matthew Roden has upgraded the stock to Buy from Neutral.
- "We find CELG compares favorably to other names in healthcare and the broader markets on the basis of EPS growth (26% vs 16% HC and 13% S&P500), and operating margin (49% vs 13% and 16% in Q3 2013, and 60% achievable for CELG by 2017)," Roden notes.
- Price target is $200.
UBS upgrade lifts Celgene
Dec 5 2013, 12:16 ET